Shopping Cart
Remove All
Your shopping cart is currently empty
Armepavine (R-Armepavine) exerted both in vitro and in vivo antifibrotic effects in rats, with inhibition of NF-κB, JunD and C/EBP pathways. It improves experimental autoimmune crescentic glomerulonephritis.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $112 | - | In Stock | |
| 5 mg | $277 | - | In Stock | |
| 10 mg | $472 | - | In Stock | |
| 25 mg | $759 | - | In Stock |
| Description | Armepavine (R-Armepavine) exerted both in vitro and in vivo antifibrotic effects in rats, with inhibition of NF-κB, JunD and C/EBP pathways. It improves experimental autoimmune crescentic glomerulonephritis. |
| Synonyms | R-Armepavine, (-)-Armepavine |
| Molecular Weight | 313.39 |
| Formula | C19H23NO3 |
| Cas No. | 524-20-9 |
| Smiles | COc1cc2CCN(C)[C@H](Cc3ccc(O)cc3)c2cc1OC |
| Relative Density. | 1.151g/cm3 |
| Color | White |
| Appearance | Solid |
| Storage | keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||
| Solubility Information | DMSO: 10 mM, Sonication is recommended. | ||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween-80+45% Saline: 1 mg/mL (3.19 mM), Sonication is recommeded. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||
DMSO
| |||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.